ScreenMCM: A Machine Learning-Based Product Screening Tool to Accelerate Medical Countermeasure Development

Rahul Kumar Goyal, M.S

Center for Translational Medicine

Department of Practices Sciences and Health Outcomes Research

School of Pharmacy

University of Maryland Baltimore, MD

ML is a New Tool for the Advancement of Precision Medicine



Jarugula et al. *The Journal of Clinical Pharmacology*; 2021

MCMs treat ARS and are Approved by US-FDA after Animal Testing

MCM

*MCM – medical countermeasure

Acute Radiation Syndrome (ARS)

Necrosis of Bone Marrow Cells

(Myelosuppression)

Mortality

Cytopenia

Product in development

Tested in Animals

FDA Approved Product

https://www.fda.gov/emergency-preparedness-and-response/mcm-regulatory-science/animal-rule-information

Failure Rate

75%

ScreenMCM Accelerates Product Screening

	Trial Duration	Sample size
Current status	60 days 0 10 20 30 40 50 60	
With tool	10 days 0 10 20 30 40 50 60	

FDA Modernization Act 2.0: This bill authorizes the use of certain alternatives to animal testing, including cell-based assays and **computer models**, to obtain an exemption from the US-FDA to investigate the safety and **effectiveness of a drug**

https://www.congress.gov/bill/117th-congress/senate-bill/5002

ScreenMCM Was Built by Pooling Existing Data

BIG DATA

01 3 studies

02 501 non-human primates

03 12 biomarkers

04 Daily data for 60 days

05 5 radiation doses



Study Designs and Data



12 Biomarkers

- RBC, HGB, HCT, RETI, PLAT
- WBC, ANC, ALC, MONO, LGUNSCE, BASO, EOS

Blood sampling times

- 1-30 days – Daily
- 31-60 days – Every 3 days

Animals

- 501
- ~15k rows of data

[1]Final Study Report, Study14-045 Lovelace Biomedical Research Institute, Doyle-Eisele M, et al
[2]Final Study Report, Study TSK-0144 CiToxLabs, Ascah A, et. al. [3]Final Study Report Study 1017-3493, CitTox Labs, Pouliot M, et. al.

3 studies – 60 days each | **501 animals** | **12 biomarkers** | **Longitudinal measurements**

Workflow to Predict Mortality due to ARS Using Supervised Machine Learning



Time Frame Selection and Data Preparation

Depletion starts – Day 4



Line is shown for mean ± standard error of the mean

4-10 days

Recovery starts – Day 13

Time window aggregation metrics

- ✓ Area under curve
- ✓ Slope
- ✓ Maximum
- ✓ Minimum
- ✓ Mean
- ✓ Auto-correlation
- ✓ Change from baseline
- ✓ Daily biomarker levels

95% Deaths in Days 12-24



Final dataset

500 animals x
136 predictors

Elastic-net regression algorithm performed similar to other algorithms based on ROC-AUC & Accuracy

Grid-search CV Results



Calibration Plot



+ Recursive feature elimination

Predictor Importance



E_NET: Elastic-net regression; RF – random forest; SVM – support vector machine; XGB - XGBoost

CFB – change from baseline, ACFn – auto-correlation factor with lag of n days, MIN – minimum, MAX - maximum

Final Elastic-net Regression Model Provides Greater than 70% Accuracy and ROC-AUC on the Test (Unseen) Dataset

Metric	Value[1]	95% CI[2]
Accuracy	**0.71**	(0.66, 0.77)
ROC-AUC	**0.75**	(0.67, 0.81)
Balanced Accuracy	0.63	(0.57, 0.7)
F1 Score	0.80	(0.77, 0.84)
MCC[3]	0.31	(0.17, 0.46)
NPV[4]	0.63	(0.51, 0.77)
PPV[5]	0.73	(0.7, 0.78)

[1]Value refers to test performance on the test dataset
[2]95% CI was obtained using 2000 bootstraps on the test dataset
[3]Matthew's Correlation Coefficient
[4]Negative Predictive Value
[5]Positive Predictive Value

Application of ScreenMCM

Products in pipeline	*Hypothetical treatment effect on platelets*	Placebo survival rate	ScreenMCM	Treatment survival rate
Product 1	*No effect*	23%		23%
Product 2	*10%*			23%
Product 3	*50%*			40%
Product 4	*100%*			47%

Conclusions



Machine Learning is Being Expanded Across Therapeutic Areas to Achieve the Goal of Precision Medicine

Individualized treatment planning for lung cancer


Volume 25, Issue 14
15 July 2019
Clinical Cancer Research

PRECISION MEDICINE AND IMAGING | JULY 15 2019

Machine Learning to Build and Validate a Model for Radiation Pneumonitis Prediction in Patients with Non–Small Cell Lung Cancer FREE

Hao Yu; Huanmei Wu; Weili Wang; Shruti Jolly; Jian-Yue Jin; Chen Hu; Feng-Ming (Spring) Kong



Biomarker identification for immunotherapy


THE LANCET
Oncology

ARTICLES | VOLUME 19, ISSUE 9, P1180-1191, SEPTEMBER 2018

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

Roger Sun, MD • Elaine Johanna Limkin, MD • Maria Vakalopoulou, PhD • Laurent Dercle, MD • Stéphane Champiat, MD • Shan Rong Han, MD • et al. Show all authors • Show footnotes



Acknowledgments & Conflicts of Interest

- Partner Therapeutics, Inc. is the project sponsor.
- Data used in this analysis was generated in three NHP studies supporting Leukine®'s FDA-approval as a MCM to treat Acute Radiation Syndrome which were funded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA), under Contract number HHSO1002013000051.
- Thank you to the collaborators for problem formulation, funding, guidance, and critique
  - Mathangi Gopalakrishnan, University of Maryland Baltimore
  - Joga Gobburu, University of Maryland Baltimore
  - John L. McManus, Partner Therapeutics

Thank You